Axsome Therapeutics Target Price

See Axsome Therapeutics's analyst price targets ($300) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$203.1

Average Target Price

$295.22

45.4% upside

9 analysts in the last 4 months

High: $380 | Low: $251

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-12	Mizuho SecuritiesGraig Suvannavejh	$316	55.6% upside
2026-08-11	RBC CapitalLeonid Timashev	$297	46.2% upside
2026-08-11	Morgan Stanley	$251	23.6% upside
2026-08-11	NeedhamAmi Fadia	$268	32% upside
2026-08-11	Guggenheim	$275	35.4% upside
2026-08-11	Wells Fargo	$256	26% upside
2026-07-20	BMO CapitalMalcolm Hoffman	$310	52.6% upside
2026-07-07	RBC CapitalLeonid Timashev	$304	49.7% upside
2026-06-11	JefferiesAndrew Tsai	$380	87.1% upside
2026-05-05	Deutsche BankDavid Hoang	$280	37.9% upside
2026-05-05	Morgan Stanley	$242	19.2% upside
2026-05-05	Needham	$267	31.5% upside
2026-05-05	RBC CapitalLeonid Timashev	$302	48.7% upside
2026-05-05	Robert W. BairdBrian Skorney	$246	21.1% upside
2026-05-05	H.C. Wainwright	$290	42.8% upside
2026-05-04	Oppenheimer	$280	37.9% upside
2026-05-04	GuggenheimYatin Suneja	$260	28% upside
2026-05-04	Piper Sandler	$258	27% upside
2026-05-04	Cantor Fitzgerald	$272	33.9% upside
2026-05-04	JefferiesAndrew Tsai	$275	35.4% upside
2026-05-04	Deutsche BankDavid Hoang	$281	38.4% upside
2026-05-04	H.C. WainwrightRaghuram Selvaraju	$270	32.9% upside
2026-05-01	Oppenheimer	$250	23.1% upside
2026-04-30	Morgan Stanley	$217	6.8% upside
2026-04-10	UBS	$259	27.5% upside
2026-02-24	RBC Capital	$222	9.3% upside
2026-02-24	UBS	$251	23.6% upside
2026-02-24	Morgan Stanley	$207	1.9% upside
2026-02-24	Guggenheim	$220	8.3% upside
2026-02-24	Wells Fargo	$202	0.5% downside
2026-02-23	Wolfe ResearchRudy Li	$230	13.2% upside
2026-02-23	Truist FinancialJoon Lee	$200	1.5% downside
2026-02-23	Jefferies	$215	5.9% upside
2026-02-19	Mizuho Securities	$230	13.2% upside
2026-01-21	RBC CapitalLeonid Timashev	$219	7.8% upside
2026-01-20	H.C. Wainwright	$260	28% upside
2026-01-16	Piper Sandler	$223	9.8% upside
2026-01-13	Robert W. Baird	$209	2.9% upside
2026-01-13	Wells Fargo	$193	5% downside
2026-01-08	Morgan Stanley	$204	0.4% upside
2026-01-06	UBS	$248	22.1% upside
2026-01-05	NeedhamAmi Fadia	$225	10.8% upside
2026-01-05	H.C. WainwrightRaghuram Selvaraju	$200	1.5% downside
2026-01-02	GuggenheimYatin Suneja	$205	0.9% upside
2025-12-31	Mizuho SecuritiesGraig Suvannavejh	$217	6.8% upside
2025-12-31	OppenheimerJay Olson	$220	8.3% upside
2025-11-04	H.C. Wainwright	$185	8.9% downside
2025-11-04	RBC Capital	$198	2.5% downside
2025-11-04	Morgan Stanley	$196	3.5% downside
2025-11-04	Wells Fargo	$157	22.7% downside

Axsome Therapeutics (AXSM) FAQ

Axsome Therapeutics posts a target price of $300. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $300 for AXSM means covering analysts, on average, see the stock 45.4% upside of $203.1 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for AXSM's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Axsome Therapeutics's other metric pages and overview cover the third.

Judging Axsome Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $300 here, then scan peer and history charts to see if the gap is persistent.